Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2012

01-11-2012 | Erratum

Erratum to: Comparison of relative versus absolute arm size change as criteria for quantifying breast cancer-related lymphedema: the flaws in current studies and need for universal methodology

Authors: Marek Ancukiewicz, Cynthia L. Miller, Melissa N. Skolny, Jean O’Toole, Laura E. Warren, Lauren S. Jammallo, Michelle C. Specht, Alphonse G. Taghian

Published in: Breast Cancer Research and Treatment | Issue 2/2012

Login to get access

Excerpt

The original publication of the article has been published with an incorrect reference. The corrected reference [52] should read as given below. …
Literature
52.
Ward LC, Bunce IH, Cornish BH, Mirolo B, Thomas BJ, Jones LC (1992) Multifrequency bioelectrical impedance augments the diagnosis and management of lymphedema in post-mastectomy patients. Eur J Clin Invest 22:751–754PubMedCrossRef
Metadata
Title
Erratum to: Comparison of relative versus absolute arm size change as criteria for quantifying breast cancer-related lymphedema: the flaws in current studies and need for universal methodology
Authors
Marek Ancukiewicz
Cynthia L. Miller
Melissa N. Skolny
Jean O’Toole
Laura E. Warren
Lauren S. Jammallo
Michelle C. Specht
Alphonse G. Taghian
Publication date
01-11-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2241-z

Other articles of this Issue 2/2012

Breast Cancer Research and Treatment 2/2012 Go to the issue

Review

Mitochondria organelle transplantation: introduction of normal epithelial mitochondria into human cancer cells inhibits proliferation and increases drug sensitivity

Preclinical Study

Targeting the HOX/PBX dimer in breast cancer

Clinical Trial

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study

Preclinical Study

mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo

Epidemiology

Breast cancer incidence by estrogen receptor status in Denmark from 1996 to 2007

Epidemiology

Through the lens of culture: quality of life among Latina breast cancer survivors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits